Cintia Carella

Cintia Carella

Auto-generated profile, based on publicly available information

Cintia Carella

Core Facilities, Italian National Institute of Health, 00161 Rome, Italy

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2013 in Nature
Verified
Journal Article
Closed access
PDF file
ASAlejandra Sanjuan-Pla
Alejandra Sanjuan-Pla
IMIain C. Macaulay
Iain C. Macaulay
CJChristina T. Jensen
Christina T. Jensen
PWPetter S. Woll
Petter S. Woll
TLTiago C. Luis
Tiago C. Luis
SJSten Eirik W. Jacobsen
Sten Eirik W. Jacobsen

19 February 2012 in Nature Immunology
Verified
Journal Article
Open access
PDF file
SLSidinh Luc
Sidinh Luc
TLTiago C Luis
Tiago C Luis
HBHanane Boukarabila
Hanane Boukarabila
IMIain C Macaulay
Iain C Macaulay
NBNatalija Buza-Vidas
Natalija Buza-Vidas
SJSten Eirik W Jacobsen
Sten Eirik W Jacobsen
The commitment stage at which progenitors seed the thymus remains unclear. Jacobsen and colleagues show that the earliest progenitors in the neonatal thymus have combined myeloid, T lymphocyte and B lymphocyte potential but not megakaryocyte-erythroid potential. The stepwise commitment from hematopoietic stem cells in the bone marrow to T lymphocyte–restricted progenitors in the thymus represents a paradigm for understanding the requirement for distinct extrinsic cues during different stages of lineage restriction from multipotent to lineage-restricted progenitors. However, the commitment stage at which progenitors migrate from the bone marrow to the thymus remains unclear. Here we provide functional and molecular evidence at the single-cell level that the earliest progenitors in the neonatal thymus had combined granulocyte-monocyte, T lymphocyte and B lymphocyte lineage potential but not megakaryocyte-erythroid lineage potential. These potentials were identical to those of candidate thymus-seeding progenitors in the bone marrow, which were closely related at the molecular level. Our findings establish the distinct lineage-restriction stage at which the T cell lineage–commitment process transits from the bone marrow to the remote thymus.

24 May 2007 in Leukemia
Verified
Journal Article
Closed access
CCC Carella
C Carella
JBJ Bonten
J Bonten
SSS Sirma
S Sirma
TKT A Kranenburg
T A Kranenburg
STS Terranova
S Terranova
GGGerard C Grosveld
Gerard C Grosveld

1 April 1999 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
CLClaudio Luparello
Claudio Luparello
GAGrazia Avanzato
Grazia Avanzato
CCCintia Carella
Cintia Carella
IPIda Pucci‐Minafra
Ida Pucci‐Minafra

1 February 2006 in Blood
Verified
Journal Article
Closed access
PDF file
CCCintia Carella
Cintia Carella
MPMark Potter
Mark Potter
JBJacqueline Bonten
Jacqueline Bonten
JRJerold E. Rehg
Jerold E. Rehg
GNGeoffrey Neale
Geoffrey Neale
GGGerard C Grosveld
Gerard C Grosveld
TEL2/ETV7 is highly homologous to the ETS transcription factor TEL/ETV6, a frequent target of chromosome translocation in human leukemia. Although both proteins are transcriptional inhibitors binding similar DNA recognition sequences, they have opposite biologic effects: TEL inhibits proliferation while TEL2 promotes it. In addition, forced expression of TEL2 but not TEL blocks vitamin D3–induced differentiation of U937 and HL60 myeloid cells. TEL2 is expressed in the hematopoietic system, and its expression is up-regulated in bone marrow samples of some patients with leukemia, suggesting a role in oncogenesis. Recently we also showed that TEL2 cooperates with Myc in B lymphomagenesis in mice. Here we show that forced expression of TEL2 alone in mouse bone marrow causes a myeloproliferative disease with a long latency period but with high penetrance. This suggested that secondary mutations are necessary for disease development. Treating mice receiving transplants with TEL2-expressing bone marrow with the chemical carcinogen N-ethyl-N-nitrosourea (ENU) resulted in significantly accelerated disease onset. Although the mice developed a GFP-positive myeloid disease with 30% of the mice showing elevated white blood counts, they all died of T-cell lymphoma, which was GFP negative. Together our data identify TEL2 as a bona fide oncogene, but leukemic transformation is dependent on secondary mutations.

27 March 2005 in Molecular and Cellular Biology
Verified
Journal Article
Open access
PDF file
MCMonica Cardone
Monica Cardone
AKAyten Kandilci
Ayten Kandilci
CCCintia Carella
Cintia Carella
JNJonas A. Nilsson
Jonas A. Nilsson
JBJennifer A. Brennan
Jennifer A. Brennan
GGGerard C Grosveld
Gerard C Grosveld
The human ETS family gene TEL2/ETV7 is highly homologous to TEL1/ETV6, a frequent target of chromosome translocations in human leukemia and specific solid tumors. Here we report that TEL2 augments the proliferation and survival of normal mouse B cells and dramatically accelerates lymphoma development in Eμ-Myc transgenic mice. Nonetheless, inactivation of the p53 pathway was a hallmark of all TEL2/Eμ-Myc lymphomas, indicating that TEL2 expression alone is insufficient to bypass this apoptotic checkpoint. Although TEL2 is infrequently up-regulated in human sporadic Burkitt's lymphoma, analysis of pediatric B-cell acute lymphocytic leukemia (B-ALL) samples showed increased coexpression of TEL2 and MYC and/or MYCN in over one-third of B-ALL patients. Therefore, TEL2 and MYC also appear to cooperate in provoking a cadre of human B-cell malignancies.